Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation.
Yuequan ShiYan XuMengzhao WangPublished in: BMC cancer (2024)
This study investigated the current diagnosis and treatment status and physicians' perspective, of patients with EGFR exon20ins-mutant NSCLC. The results highlight significant unmet clinical needs in this subgroup of patients. EGFR exon20ins-targeted TKIs were recognized as the most promising treatment regimen and may benefit more patients considering their awareness and acceptance of targeted therapy.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- end stage renal disease
- tyrosine kinase
- small cell lung cancer
- ejection fraction
- newly diagnosed
- primary care
- chronic kidney disease
- clinical practice
- prognostic factors
- clinical trial
- high resolution
- cancer therapy
- smoking cessation
- replacement therapy
- double blind